Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy.
Lancet Oncol. 2011 Nov;12(12):1151-61. doi: 10.1016/S1470-2045(11)70131-0. Epub 2011 Jun 28.
Development of advanced and high-throughput methods to study variability in human genes means we can now use pharmacogenomic analysis not only to predict response to treatment but also to assess the toxic action of drugs on normal cells (so-called toxicogenomics). This technological progress could enable us to identify individuals at high and low risk for a given side-effect. Pharmacogenomics could be very useful for stratification of cancer patients at risk of developing chemotherapy-induced peripheral neurotoxicity, one of the most severe and potentially permanent non-haematological side-effects of modern chemotherapeutic agents. However, study data reported so far are inconsistent, which suggests that methodological improvement is needed in clinical trials to obtain reliable results in this clinically relevant area.
开发先进的高通量方法来研究人类基因的变异性意味着我们现在不仅可以使用药物基因组学分析来预测治疗反应，还可以评估药物对正常细胞的毒性作用（所谓的毒代动力学基因组学）。这项技术进步可以使我们能够识别出具有特定副作用高风险和低风险的个体。药物基因组学对于分层患有化疗引起的周围神经毒性风险的癌症患者可能非常有用，这是现代化疗药物最严重和潜在永久性的非血液学副作用之一。然而，迄今为止报告的研究数据不一致，这表明需要在临床试验中改进方法学，以在这一具有临床相关性的领域获得可靠的结果。
